Surgical Outcome in Retroperitoneal Sarcoma Surgery: Accuracy of P-POSSUM, ACS-NSQIP, and Inflammatory Biomarkers Prognostic Index (IBPI) Risk-Calculators for Prediction of Severe and Overall Morbidity.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 20 03 2024
accepted: 08 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Retroperitoneal sarcoma often requires comprehensive resection, leading to severe postoperative morbidity. The lack of disease-procedure specific tools for morbidity risk and the questionable accuracy of existing tools (ACS-NSQIP and P-POSSUM) in RPS surgery drove this study to assess these calculators' accuracy. Retrospective analysis of primary RPS cases undergoing surgery at two sarcoma-referral centers was conducted. Predicted morbidity/mortality rates at 90 days postsurgery, classified by Clavien-Dindo (CD) and Comprehensive Complication Index (CCI), were compared with observed data. Accuracy was assessed by Brier Score and area under the curve (AUC). Inflammatory Biomarkers Prognostic Index (IBPI) also was tested. A total of 567 patients (median age 62 years; 53.6% male) with a median of four resected organs were included. 59% experienced surgical complications by 90 days postoperation, graded CD ≥ 3 in 30.5%, median CCI 20.9, with a mortality rate of 1.6% (8/567). Reoperation was required in 68 of 567 patients (12%). Thirty-day mortality was 1.1%. Severe complications occurred after 30th postoperative day in 3.5% cases. ACS-NSQIP predicted below-average complication for 65.1%, average for 16.9%, and above-average for 18% of patients. P-POSSUM predicted a 66% rate of morbidity and 4% mortality. None of the prediction tools were accurate, with Brier scores ranging 0.155-0.231 and no AUC ≥ 0.7. IBPI accuracy for predicting severe infective complication was low (AUC 0.58, Brier 0.161). The significant morbidity burden after MVR necessitates reliable evaluation, especially in frail patients. Given the limitations of ACS-NSQIP and P-POSSUM, a dedicated prediction tool for perioperative events in RPS candidates for MVR needs urgent development.

Identifiants

pubmed: 39060686
doi: 10.1245/s10434-024-15861-1
pii: 10.1245/s10434-024-15861-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Society of Surgical Oncology.

Références

Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma (RPS) in the ADULT: an updated consensus approach from the transatlantic Australasian RPS working group. Ann Surg Oncol. 2021;28(12):7873–88. https://doi.org/10.1245/s10434-021-09654-z .
doi: 10.1245/s10434-021-09654-z pubmed: 33852100 pmcid: 9257997
MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the transatlantic RPS working group. Ann Surg. 2018;267(5):959–64. https://doi.org/10.1097/SLA.0000000000002250 .
doi: 10.1097/SLA.0000000000002250 pubmed: 28394870
Bilimoria KY, Liu Y, Paruch JL, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg. 2013;217(5):833–42. https://doi.org/10.1016/j.jamcollsurg.2013.07.385 .
doi: 10.1016/j.jamcollsurg.2013.07.385 pubmed: 24055383 pmcid: 3805776
Prytherch DR, Whiteley MS, Higgins B, Weaver PC, Prout WG, Powell SJ. POSSUM and Portsmouth POSSUM for predicting mortality. Br J Surg. 1998;85(9):1217–20. https://doi.org/10.1046/j.1365-2168.1998.00840.x .
doi: 10.1046/j.1365-2168.1998.00840.x pubmed: 9752863
Mukherjee S, Kedia A, Goswami J, Chakraborty A. Validity of P-POSSUM in adult cancer surgery (PACS). J Anaesthesiol Clin Pharmacol. 2022;38(1):61–5. https://doi.org/10.4103/joacp.JOACP_128_20 .
doi: 10.4103/joacp.JOACP_128_20 pubmed: 35706623 pmcid: 9191788
Schwartz PB, Stahl CC, Ethun C, et al. Retroperitoneal sarcoma perioperative risk stratification: a United States Sarcoma Collaborative evaluation of the ACS-NSQIP risk calculator. J Surg Oncol. 2020. https://doi.org/10.1002/jso.26071.10.1002/jso.26071 .
doi: 10.1002/jso.26071.10.1002/jso.26071 pubmed: 32939750 pmcid: 7770044
Fiore M, Ljevar S, Pasquali S, et al. Preoperative neutrophil-to-lymphocyte ratio and a new inflammatory biomarkers prognostic index for primary retroperitoneal sarcomas: retrospective monocentric study. Clin Cancer Res. 2023;29(3):614–20. https://doi.org/10.1158/1078-0432.CCR-22-2897 .
doi: 10.1158/1078-0432.CCR-22-2897 pubmed: 36478176
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae .
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 1360123
Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):1–7. https://doi.org/10.1097/SLA.0b013e318296c732 .
doi: 10.1097/SLA.0b013e318296c732 pubmed: 23728278
Anderson WJ, Doyle LA. Updates from the 2020 world health organization classification of soft tissue and bone tumours. Histopathology. 2021;78(5):644–57. https://doi.org/10.1111/his.14265 .
doi: 10.1111/his.14265 pubmed: 33438273
Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42. https://doi.org/10.1002/ijc.2910330108 .
doi: 10.1002/ijc.2910330108 pubmed: 6693192
Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG bone and soft tissue tumor study group. Jpn J Clin Oncol. 2019;49(2):103–7. https://doi.org/10.1093/jjco/hyy157 .
doi: 10.1093/jjco/hyy157 pubmed: 30423153
Fiore M, Baia M, Conti L, et al. Residual adrenal function after multivisceral resection with adrenalectomy in adult patients. JAMA Surg. 2022;157(5):415–23. https://doi.org/10.1001/jamasurg.2021.7588 .
doi: 10.1001/jamasurg.2021.7588 pubmed: 35195679 pmcid: 8867388
Tirotta F, Parente A, Richardson, et al. Comparison of comprehensive complication index and Clavien-Dindo classification in patients with retroperitoneal sarcoma. J Surg Oncol. 2021;124(7):1166–72. https://doi.org/10.1002/jso.26612 .
doi: 10.1002/jso.26612 pubmed: 34287906
Ruspi L, Cananzi FCM, Aymerito F, et al. Measuring the impact of complications after surgery for retroperitoneal sarcoma: Is comprehensive complication index better than Clavien-Dindo classification? Eur J Surg Oncol. 2022;48(5):978–84. https://doi.org/10.1016/j.ejso.2021.12.010 .
doi: 10.1016/j.ejso.2021.12.010 pubmed: 34903429
Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. vol 398, Hoboken: Wiley; 2013.
doi: 10.1002/9781118548387
Zhuang A, Chen Y, Ma L, et al. Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma. BMC Surg. 2023;23(1):42. https://doi.org/10.1186/s12893-023-01941-8.PMID:36814201;PMCID:PMC9948406 .
doi: 10.1186/s12893-023-01941-8.PMID:36814201;PMCID:PMC9948406 pubmed: 36814201 pmcid: 9948406
Tirotta F, Parente A, Hodson J, Desai A, Almond LM, Ford SJ. Cumulative burden of postoperative complications in patients undergoing surgery for primary retroperitoneal sarcoma. Ann Surg Oncol. 2021;28(12):7939–49. https://doi.org/10.1245/s10434-021-10059-1 .
doi: 10.1245/s10434-021-10059-1 pubmed: 33978886

Auteurs

Michela Angelucci (M)

U.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.

Marco Baia (M)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. marco.baia@istitutotumori.mi.it.

Marilù Garo (M)

Independent Research, Rome, Italy.

Rossana Alloni (R)

Department of Medicine and Surgery, Università Campus BioMedico, Rome, Italy.

Dario Callegaro (D)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Chiara Pagnoni (C)

U.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.

Stefano Radaelli (S)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Chiara Colombo (C)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Sandro Pasquali (S)

Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Alessandro Gronchi (A)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Sergio Valeri (S)

U.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.

Marco Fiore (M)

S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Classifications MeSH